US Bancorp’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.3M Sell
5,735
-512
-8% -$91.2K ﹤0.01% 1071
2026
Q1
$1.08M Sell
6,247
-1,276
-17% -$237K ﹤0.01% 1108
2025
Q4
$1.5M Buy
7,523
+1,958
+35% +$355K ﹤0.01% 994
2025
Q3
$871K Buy
5,565
+214
+4% +$34K ﹤0.01% 1207
2025
Q2
$812K Sell
5,351
-2,960
-36% -$395K ﹤0.01% 1216
2025
Q1
$1.25M Sell
8,311
-837
-9% -$140K ﹤0.01% 1027
2024
Q4
$1.69M Sell
9,148
-4,578
-33% -$882K ﹤0.01% 926
2024
Q3
$2.7M Sell
13,726
-7,851
-36% -$1.63M ﹤0.01% 761
2024
Q2
$4.46M Sell
21,577
-223
-1% -$50.5K 0.01% 603
2024
Q1
$5.91M Sell
21,800
-2,863
-12% -$684K 0.01% 541
2023
Q4
$5.83M Sell
24,663
-1,719
-7% -$338K 0.01% 538
2023
Q3
$5.17M Buy
26,382
+613
+2% +$126K 0.01% 540
2023
Q2
$5.42M Sell
25,769
-1,419
-5% -$282K 0.01% 539
2023
Q1
$5.49M Sell
27,188
-10,037
-27% -$2.27M 0.01% 535
2022
Q4
$8.11M Sell
37,225
-410
-1% -$89.5K 0.01% 447
2022
Q3
$7.41M Buy
37,635
+10,984
+41% +$2.37M 0.02% 425
2022
Q2
$5.7M Buy
26,651
+143
+0.5% +$34.9K 0.01% 503
2022
Q1
$7.53M Buy
26,508
+2,436
+10% +$751K 0.01% 476
2021
Q4
$9.07M Buy
24,072
+205
+0.9% +$79.6K 0.01% 441
2021
Q3
$9.85M Sell
23,867
-94
-0.4% -$39K 0.02% 406
2021
Q2
$8.86M Sell
23,961
-104
-0.4% -$34.7K 0.02% 433
2021
Q1
$6.97M Buy
24,065
+292
+1% +$81.2K 0.01% 477
2020
Q4
$5.94M Sell
23,773
-1,167
-5% -$278K 0.01% 489
2020
Q3
$5.65M Sell
24,940
-1,424
-5% -$296K 0.01% 469
2020
Q2
$4.6M Sell
26,364
-1,610
-6% -$257K 0.01% 501
2020
Q1
$3.53M Buy
27,974
+1,937
+7% +$291K 0.01% 518
2019
Q4
$3.98M Sell
26,037
-1,958
-7% -$271K 0.01% 578
2019
Q3
$3.71M Buy
27,995
+523
+2% +$70.1K 0.01% 584
2019
Q2
$3.9M Buy
27,472
+2,790
+11% +$378K 0.01% 573
2019
Q1
$3.59M Sell
24,682
-1,681
-6% -$221K 0.01% 570
2018
Q4
$2.98M Sell
26,363
-2,144
-8% -$268K 0.01% 596
2018
Q3
$3.83M Sell
28,507
-139
-0.5% -$17.2K 0.01% 583
2018
Q2
$3.22M Sell
28,646
-1,639
-5% -$177K 0.01% 633
2018
Q1
$3.23M Buy
30,285
+5,867
+24% +$632K 0.01% 629
2017
Q4
$2.67M Buy
24,418
+6,203
+34% +$675K 0.01% 682
2017
Q3
$1.97M Buy
18,215
+15,448
+558% +$1.59M 0.01% 794
2017
Q2
$281K Hold
2,767
﹤0.01% 1675
2017
Q1
$248K Sell
2,767
-67
-2% -$5.69K ﹤0.01% 1714
2016
Q4
$217K Buy
2,834
+112
+4% +$8.51K ﹤0.01% 1757
2016
Q3
$227K Sell
2,722
-156
-5% -$13.1K ﹤0.01% 1702
2016
Q2
$237K Sell
2,878
-243
-8% -$20K ﹤0.01% 1644
2016
Q1
$236K Sell
3,121
-17
-0.5% -$1.26K ﹤0.01% 1621
2015
Q4
$252K Sell
3,138
-687
-18% -$49.5K ﹤0.01% 1597
2015
Q3
$243K Sell
3,825
-2,070
-35% -$149K ﹤0.01% 1641
2015
Q2
$414K Sell
5,895
-1,196
-17% -$88.5K ﹤0.01% 1438
2015
Q1
$562K Sell
7,091
-184
-3% -$13.6K ﹤0.01% 1305
2014
Q4
$463K Buy
7,275
+795
+12% +$49.8K ﹤0.01% 1364
2014
Q3
$387K Buy
6,480
+2,089
+48% +$120K ﹤0.01% 1447
2014
Q2
$235K Buy
4,391
+595
+16% +$32.6K ﹤0.01% 1726
2014
Q1
$229K Buy
3,796
+452
+14% +$26.3K ﹤0.01% 1704
2013
Q4
$177K Sell
3,344
-4,338
-56% -$218K ﹤0.01% 1793
2013
Q3
$355K Buy
7,682
+4,887
+175% +$224K ﹤0.01% 1404
2013
Q2
$115K Buy
+2,795
New +$120K ﹤0.01% 1947

Other funds holding CRL

US Bancorp's CRL Position: Q2 2026 in Review

US Bancorp reduced its Charles River Laboratories (CRL) stake by 8.2% in Q2 2026, selling an estimated $91.2K and leaving 5,735 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

US Bancorp first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.85M in Q3 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • US Bancorp held 5,735 shares of Charles River Laboratories worth $1.3M as of Q2 2026.
  • US Bancorp sold 512 Charles River Laboratories shares in Q2 2026, an estimated $91.2K.
  • Charles River Laboratories made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1071 holding.
  • US Bancorp first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's Charles River Laboratories position peaked at $9.85M in Q3 2021.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.